DIPG: 13-year-old boy reported as the first patient cured after a clinical trial

A 13-year-old diagnosed with diffuse intrinsic pontine glioma (DIPG) took part in the BIOMEDE clinical trial and is reported to be tumor-free after treatment with everolimus; several other trial participants have been long responders.

A 13-year-old boy from Belgium is reported to have become the first person cured of diffuse intrinsic pontine glioma (DIPG) after participating in a clinical trial. DIPG is a highly aggressive childhood brain tumor that has been historically fatal and difficult to treat. The boy joined the BIOMEDE trial in France and was assigned the drug everolimus, which was not previously used for DIPG. Medical teams and researchers say the case raises new questions about tumor biology and next research steps. Known details: - The patient, named Lucas Jemeljanova, was diagnosed with DIPG at age six and is now reported to be 13. - Lucas took part in the BIOMEDE clinical trial in France and was randomly assigned everolimus as the study medication. - Everolimus blocks the mTOR protein and is approved for other cancers; it had not been used for DIPG before this trial. - Over a series of MRI scans reported by doctors, the tumor is said to have completely disappeared and has not returned; he is considered officially cured. - Seven other children in the trial were described as "long responders," with tumors not progressing for more than three years after starting everolimus. - Doctors and researchers said an uncommon genetic mutation in Lucas' tumor may have made it more sensitive to the drug, and teams plan to study tumor organoids and other models to understand the response. Summary: Lucas' reported recovery marks a rare outcome for a disease long considered uniformly fatal and is reported by clinicians as a meaningful case for researchers. The next steps described by trial researchers include studying why this tumor responded, using organoids and other laboratory methods to replicate the effect, and continuing clinical research to identify treatments that work across more patients.